P. Poureau

Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.

G. Quéré, R. Descourt, G. Robinet, 2019, European journal of cancer.

MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer.

N. Rioux-Leclercq, F. Beuvon, A. Lièvre, 2022, Clinics and research in hepatology and gastroenterology.

Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.

I. Soubeyran, M. Toulmonde, A. Italiano, 2022, European journal of cancer.

Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.

I. Soubeyran, A. Italiano, T. Mazard, 2021 .

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.

E. Van Cutsem, J. Tabernero, M. Fakih, 2023, Journal of Clinical Oncology.

Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.

E. Van Cutsem, J. Tabernero, M. Fakih, 2023, The New England journal of medicine.

Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.

D. Botsen, S. Ammari, P. Decazes, 2024, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.